Nkarta's NK Cell Therapy Shows First Human Data in Autoimmune

Nkarta is presenting its first human data for a natural killer (NK) cell therapy aimed at autoimmune disease at the American College of Rheumatology annual meeting in Orlando, according to MedCity News. The early results, covering patients with myositis and systemic sclerosis, show the treatment was safe and produced signs of efficacy.

The approach borrows from oncology. Cell therapies that deplete immune cells driving disease can effectively reset a malfunctioning immune system. Nkarta joins a widening group of biotechs chasing this idea in autoimmune conditions, where the goal is durable remission rather than lifelong symptom management with immunosuppressants.

NK cell therapies are being positioned as a potentially simpler, off-the-shelf alternative to engineered T-cell treatments, which require complex manufacturing. Early safety and efficacy signals are a meaningful first step, but the data remain preliminary and involve small patient numbers. Larger, controlled trials will determine whether the effect holds and how it compares with other immune-resetting strategies now in development.